Business Context and Reporting Period
This Form 8-K Current Report was filed by Maiden Holdings, Ltd. on January 30, 2019. The filing details significant strategic actions taken to address regulatory capital requirements and restructure relationships with AmTrust Financial Services, Inc. The primary focus is the termination of long-standing reinsurance agreements and the amendment of related loan and master agreements to facilitate a run-off of business and cure a breach of the Bermuda Enhanced Capital Requirement (ECR).
Key Financial Metrics and Agreements
The filing does not provide specific revenue, profit, or cash flow figures for a reporting period. However, it outlines critical financial arrangements and capital actions:
- Capital Cure: The Company has cured a previously reported breach of the Bermuda Enhanced Capital Requirement (ECR) through terminated reinsurance agreements, a partial termination amendment, and a cash injection from the sale of Maiden Reinsurance North America, Inc.
- Loan Maturity Extension: The maturity date for loans under the Loan Agreement between Maiden Bermuda and AmTrust entities has been extended to January 1, 2025.
- Withheld Funds Interest:
- For the U.S./Global Quota Share termination: AmTrust will pay Maiden a fixed annual interest rate of 3.50% on Withheld Funds, subject to security requirements.
- For the European Quota Share termination: AmTrust will pay Maiden a fixed annual interest rate of 50 basis points (0.50%) on Withheld Funds, subject to security requirements.
- Future Lending: No further loans or advances may be made pursuant to the amended Loan Agreement.
Material Changes Versus Prior Period
The filing reports a fundamental shift in the Company's business model and capital structure effective January 1, 2019:
- Termination of Reinsurance: Maiden terminated two major Quota Share agreements with AmTrust on a run-off basis:
- The Amended and Restated Quota Share Agreement (originally 2007) covering U.S., Irish, and U.K. business.
- The Quota Share Reinsurance Contract (originally 2011) covering 60% of AmTrust's European medical liability business.
Regulatory Status: The Company moved from a state of ECR breach to a cured status, with expectations of further ECR increases.
- Business Plan Restriction: The Company is in discussions with the Bermuda Monetary Authority (BMA) regarding a longer-term business plan. Any new reinsurance business requires BMA approval.
Guidance, Outlook, and Risks
Outlook and Management Commentary: Management indicates the Company is in a recovery phase of its capital base. The termination of reinsurance agreements is a strategic move to stabilize capital. The Company remains engaged with the BMA to formulate a future business plan, implying a pause on new underwriting until regulatory approval is secured.
Risks and Contingencies:
- Run-off Complexity: The Company must manage the run-off of terminated policies until their expiration or final resolution of losses.
- Regulatory Approval: Future growth is contingent on BMA approval of a new business plan.
- Interest Rate Resets: Interest rates on Withheld Funds are subject to annual resets based on market yields (e.g., USD US Corporate A+ five-year yield), introducing variability in future income from these funds.
- Investment Risk Transfer: Once Withheld Funds from the European agreement are remitted to a trust account, Maiden will assume investment risk on those assets.
Investor Verification Checklist
- Verify the exact amount of the cash injection received from the sale of Maiden Reinsurance North America, Inc.
- Confirm the current status of the Bermuda Enhanced Capital Requirement (ECR) and the specific level of capital achieved post-cure.
- Review the timeline and specific requirements for the BMA approval of the new business plan.
- Assess the volume and duration of the run-off business remaining under the terminated Quota Share agreements.
- Monitor the quarterly interest payments on Withheld Funds and the potential impact of future interest rate resets.